Chacon André Felipe Pedrazzi, Figueiredo Anna Barreto Fernandes, Boechat Jéssica Sepulveda, Reis Erica Guerino, Honorato Cindy Caroline Dos Santos, Corrêa Maria Lopes, Pereira Sandro Antonio, Gremião Isabella Dib Ferreira
Laboratório de Pesquisa Clínica em Dermatozoonoses em Animais Domésticos (Lapclin-Dermzoo), Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-360, Brazil.
Coordenação de Uma Só Saúde, Instituto de Ciência e Tecnologia em Biomodelos (ICTB), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-360, Brazil.
Vet Sci. 2025 Aug 28;12(9):830. doi: 10.3390/vetsci12090830.
Brazil is an endemic region for both human and feline sporotrichosis, with being the main etiological agent. Currently, few effective antifungal agents are available for treating this mycosis in cats, and therapeutic studies remain limited. Itraconazole (ITZ) is the first-line drug; however, its effectiveness is variable. To evaluate the use of ITZ combined with β-glucans () in feline sporotrichosis, a prospective, uncontrolled interventional study was conducted in 29 cats. Clinical cure was achieved in 21 animals (72.4%) with a median treatment duration of 10 weeks. Most of these cats presented with nasal region lesions, nasal mucosa involvement, and respiratory signs, which are commonly associated with poor therapeutic outcomes. Treatment failure occurred in 5 animals (17.2%), and 3 (10.3%) were lost to follow-up. No deaths were recorded during the study. Adverse drug reactions (ADRs) were observed in 2 cats (6.9%). These findings suggest that β-glucans may be a complementary strategy in the treatment of feline sporotrichosis, particularly in cases involving nasal lesions and respiratory signs, and may also contribute to the prevention of ADRs associated with conventional therapy.
巴西是人类和猫孢子丝菌病的流行地区， 是主要的病原体。目前，很少有有效的抗真菌药物可用于治疗猫的这种真菌病，治疗研究仍然有限。伊曲康唑（ITZ）是一线药物；然而，其疗效存在差异。为了评估ITZ联合β-葡聚糖（ ）在猫孢子丝菌病中的应用，对29只猫进行了一项前瞻性、非对照干预研究。21只动物（72.4%）实现了临床治愈，中位治疗持续时间为10周。这些猫大多出现鼻部病变、鼻黏膜受累和呼吸道症状，这些通常与治疗效果不佳有关。5只动物（17.2%）治疗失败，3只（10.3%）失访。研究期间未记录到死亡病例。2只猫（6.9%）观察到药物不良反应（ADR）。这些发现表明，β-葡聚糖可能是治疗猫孢子丝菌病的一种补充策略，特别是在涉及鼻部病变和呼吸道症状的病例中，也可能有助于预防与传统治疗相关的ADR。
